An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols.

Trial Profile

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors ArQule
  • Most Recent Events

    • 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 31 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2019.
    • 31 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top